Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Premier Invests In Exela To Procure Shortage-Hit Generic Injectables

Participating Premier Health Systems Sign Multi-Year Purchasing Commitments

Executive Summary

As hospital drug shortages continue to bite in the US, a group purchasing organization has invested in generic injectables specialist Exela Pharma Sciences to garner uninterrupted supply of 19 pharmaceutical products.

You may also be interested in...



Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

US FDA Board Formed To Manage Increasingly Complex Pharmaceutical Supply Chain Oversight

High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, CDER’s Jacqueline Corrigan-Curay, who will chair the group, tells the Pink Sheet.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel